Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
AUTL Autolus Therapeutics	$2.65 +7.3%	$1.92	$1.11 ▼ $5.00	$705.27M	1.81	1.57 million shs	1.87 million shs
AVRO AVROBIO		$9.98	$0.88 ▼ $1.65	$62.85M	1.23	269,831 shs	206,800 shs
MGTX MeiraGTx	$8.89 +5.0%	$6.16	$3.85 ▼ $8.92	$714.40M	1.24	406,584 shs	626,369 shs
PRTO Proteon Therapeutics	$3.16 +3.6%	$19.37	$0.22 ▼ $3.94	$70.09M	0.6	1.11 million shs	105,954 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	-91.97%
AUTL Autolus Therapeutics	+7.29%	+17.26%	+25.00%	+89.29%	-37.65%
AVRO AVROBIO	0.00%	0.00%	0.00%	0.00%	0.00%
MGTX MeiraGTx	+4.96%	+14.86%	+34.09%	+63.12%	+92.84%
PRTO Proteon Therapeutics	0.00%	+5.54%	-2.87%	-26.33%	+29.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.1752 of 5 stars	3.8	0.0	0.0	0.0	0.6	0.0	0.0
AUTL Autolus Therapeutics	2.7601 of 5 stars	3.5	1.0	0.0	0.0	3.0	3.3	0.6
AVRO AVROBIO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	4.2665 of 5 stars	3.5	1.0	0.0	4.8	3.2	2.5	0.6
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	251.70% Upside
AVRO AVROBIO	0.00	N/A	N/A	N/A
MGTX MeiraGTx	3.00	Buy	$24.00	169.97% Upside
PRTO Proteon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AVRO, APTO, AUTL, MGTX, and PRTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
AUTL Autolus Therapeutics	$10.12M	69.69	N/A	N/A	$1.61 per share	1.65
AVRO AVROBIO	N/A	N/A	N/A	N/A	$2.13 per share	N/A
MGTX MeiraGTx	$33.28M	21.47	N/A	N/A	$0.87 per share	10.22
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	($0.06) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
AVRO AVROBIO	$12.16M	$0.69	2.03	N/A	N/A	N/A	-50.52%	-47.13%	N/A
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	23.39	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)
PRTO Proteon Therapeutics	-$20.73M	-$1.15	N/A	N/A	N/A	N/A	N/A	-118.68%	N/A

Latest AVRO, APTO, AUTL, MGTX, and PRTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	MGTX MeiraGTx	-$0.52	N/A	N/A	N/A	$8.00 million	N/A
8/8/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
AVRO AVROBIO	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
AUTL Autolus Therapeutics	N/A	9.24	9.02
AVRO AVROBIO	N/A	26.17	26.17
MGTX MeiraGTx	2.34	1.53	1.51
PRTO Proteon Therapeutics	N/A	5.98	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
AUTL Autolus Therapeutics	72.83%
AVRO AVROBIO	62.63%
MGTX MeiraGTx	67.48%
PRTO Proteon Therapeutics	23.03%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
AUTL Autolus Therapeutics	25.70%
AVRO AVROBIO	9.20%
MGTX MeiraGTx	7.50%
PRTO Proteon Therapeutics	45.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
AVRO AVROBIO	13	44.89 million	40.76 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable
PRTO Proteon Therapeutics	17	22.18 million	N/A	Not Optionable

AVRO, APTO, AUTL, MGTX, and PRTO Headlines

Recent News About These Companies

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan

November 9, 2024 | markets.businessinsider.com

Protara Therapeutics (TARA) Earnings Dates & Reports

November 1, 2024 | investing.com

ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James

October 29, 2024 | markets.businessinsider.com

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

October 28, 2024 | msn.com

ProQR Announces Major Share Offering Agreement

October 25, 2024 | markets.businessinsider.com

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

October 22, 2024 | msn.com

Understanding Neurodegenerative Disease with Prion Research

September 13, 2024 | the-scientist.comT

Prodrugs and patents: Enhancing therapy adherence and reducing side effects

September 11, 2024 | msn.com

iPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to Expect

September 8, 2024 | macrumors.comM

PS5 Pro: the latest on rumored specs, price, and release date speculation

August 30, 2024 | techradar.comT

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

May 22, 2024 | seekingalpha.com

PTC Therapeutics: Q1 Earnings Snapshot

April 25, 2024 | timesunion.comT

Protara Therapeutics Inc (TARA)

April 24, 2024 | investing.com

iPad Pro

February 2, 2024 | macrumors.comM

Esperion Therapeutics Inc ESPR

November 5, 2023 | morningstar.comM

The Latest Analyst Ratings for Revance Therapeutics

September 20, 2023 | benzinga.com

ENLV - Enlivex Therapeutics Ltd.

June 6, 2023 | finance.yahoo.com

Prelude Therapeutics Insider Trades Send a Signal

May 25, 2023 | benzinga.com

Global Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growth

May 22, 2023 | benzinga.com

The best iPhone 14 Pro deals for May 2023

May 18, 2023 | techradar.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVRO, APTO, AUTL, MGTX, and PRTO Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Autolus Therapeutics NASDAQ:AUTL

$2.65 +0.18 (+7.29%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.67 +0.02 (+0.75%)

As of 07/14/2025 07:55 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

AVROBIO NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

MeiraGTx NASDAQ:MGTX

$8.89 +0.42 (+4.96%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$8.88 -0.01 (-0.06%)

As of 07/14/2025 07:58 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Proteon Therapeutics NASDAQ:PRTO

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time